Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.

You may also be interested in...



Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries

With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.

Dapagliflozin Faces Ominous Prospect Of New Trials

FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.

HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel